Deletion Mutants of the Attenuated Recombinant ASF Virus, BA71ΔCD2, Show Decreased Vaccine Efficacy
Visualitza/Obre
Autor/a
Lopez, Elisabeth
Bosch-Camós, Laia
Ramirez-Medina, Elizabeth
Vuono, Elizabeth
Navas, Maria Jesus
Muñoz, Marta
Zhang, Jinya
Alonso, Uxia
Salas, Maria Luisa
Anachkov, Nikolay
Gladue, Douglas P.
Borca, Manuel V.
Data de publicació
2021-08-25ISSN
1999-4915
Resum
African swine fever (ASF) has become the major threat to the global swine industry. Lack
of available commercial vaccines complicates the implementation of global control strategies. So
far, only live attenuated ASF viruses (ASFV) have demonstrated solid protection efficacy at the
experimental level. The implementation of molecular techniques has allowed the generation of a
collection of deletion mutants lacking ASFV-specific virulence factors, some of them with promising
potential as vaccine candidates against the pandemic genotype II ASFV strain currently circulating in
Africa, Europe, Asia and Oceania. Despite promising results, there is room for improvement, mainly
from the biosafety point of view. Aiming to improve the safety of BA71∆CD2, a cross-protective
recombinant live attenuated virus (LAV) lacking the ASFV CD2v gene (encoding β-glucuronidase as a
reporter gene) available in our laboratory, three new recombinants were generated using BA71∆CD2
as a template: the single mutant BA71∆CD2f, this time containing the fluorescent mCherry reporter
gene instead of CD2v, and two double recombinants lacking CD2v and either the lectin gene (EP153R)
or the uridine kinase (UK) gene (DP96R). Comparative in vivo experiments using BA71∆CD2f,
BA71∆CD2DP96R and BA71∆CD2EP153R recombinant viruses as immunogens, demonstrated that
deletion of either DP96R or EP153R from BA71∆CD2f decreases vaccine efficacy and does not
improve safety. Our results additionally confirm ASFV challenge as the only available method today
to evaluate the protective efficacy of any experimental vaccine. We believe that understanding the
fine equilibrium between attenuation and inducing protection in vivo deserves further study and
might contribute to more rational vaccine designs in the future.
Tipus de document
Article
Versió del document
Versió publicada
Llengua
Anglès
Matèries (CDU)
619 - Veterinària
Pàgines
13
Publicat per
MDPI
Publicat a
Viruses
Citació
Lopez, Elisabeth, Laia Bosch-Camós, Elizabeth Ramirez-Medina, Elizabeth Vuono, Maria Jesus Navas, Marta Muñoz, and Francesc Accensi et al. 2021. "Deletion Mutants Of The Attenuated Recombinant ASF Virus, BA71ΔCD2, Show Decreased Vaccine Efficacy". Viruses 13 (9): 1678. doi:10.3390/v13091678.
Número de l'acord de la subvenció
MINECO/Programa Estatal de I+D+I orientada a los retos de la sociedad/AGL2016-78160-C2-1-R/ES/Estrategias de protección frente a la peste porcina africana: de la investigación básica a la aplicada/
Programa
Sanitat Animal
Aquest element apareix en la col·lecció o col·leccions següent(s)
- ARTICLES CIENTÍFICS [2536]
Els següents fitxers sobre la llicència estan associats a aquest element:
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com http://creativecommons.org/licenses/by/4.0/